Biomarker testing in advanced NSCLC has increased in recent years, but turnaround time has remained roughly the same, data suggest.
Bryngaer o oes yr haearn ydi'r boncan; dyma'r 'Dinas Dinlle', neu Ddinas Lleu, gwreiddiol sydd wedi rhoi ei enw i'r traeth ...
In December 2024, Elicio announced the completion of enrollment of the randomized Phase 2 AMPLIFY-7P clinical trial ( NCT05726864 ). The trial has successfully enrolled 144 post-resection mKRAS PDAC ...
FORE Biotherapeutics has announced that two abstracts on its investigational therapy plixorafenib will be presented at the ...
SAN FRANCISCO and SUZHOU, China, March 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutic ...
Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...
Approximately 80% of individuals who receive immune checkpoint inhibitors for advanced cancer do not respond to therapy, according to results of a cross-sectional analysis.The number of FDA-approved ...
Pembrolizumab and XL888 in advanced CRC showed manageable safety, though limited responses and potential immunomodulatory ...
Mae ymgyrchwyr wedi cyhuddo Awdurdod Parc Cenedlaethol Arfordir Penfro, sydd yn rhedeg Oriel y Parc yn Nhyddewi, o "gefnu" ar ...
DelveInsight’s, “Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 195+ companies and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback